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Abstract
Background: Primary immunodeficiency disorders associated with autoimmunity are poorly understood. Central
nervous system (CNS) vasculitis can complicate the courses of such entities, but it is underappreciated. Deletion of the
dedicator of cytokinesis 8 (DOCK8) gene is considered to be the autosomal recessive form of hyperimmunoglobulin E
syndrome which is a rare type of primary immunodeficiency disease characterized by elevated levels of IgE antibody,
eczema, and recurrent staphylococcal infections. DOCK8 deletion is associated with fatal CNS vasculitis. However,
descriptions of such cases and their outcomes are scarce in the literature.
Case presentation: This report describes a young female with a DOCK8 gene deletion presenting acutely with
squint, fatigue and visual hallucinations. The patient was diagnosed as having neuritis of the third oculomotor
nerve and encephalitis, which were thought to be related to her underlying immune deficiency, however, she
subsequently was diagnosed with CNS vasculitis based on brain magnetic imaging and magnetic resonance
angiography findings. We provide here a comprehensive description of the patient’s clinical outcome and
outline an effective treatment approach that may be useful for similar patients and includes the use of
steroids and mycophenolate mofetil (MMF). The treatment was well tolerated and enabled the patient to
recover most of her neurological deficits. However, despite the initial improvement, she later developed
stroke.
Conclusions: To the best of our knowledge, this is the first report in the literature of a case of primary
immunodeficiency complicated by CNS vasculitis demonstrating a successful outcome. Our observations
indicate that the combination of MMF and steroids is an effective treatment for CNS vasculitis associated
with DOCK8 deficiency. However, lack of awareness of the neurological comorbidities associated with primary
immunodeficiencies and the delay in diagnosis likely contributed to the development of acute cerebral infarction.
Early treatment and aggressive control of the disease’s initial inflammation is essential for preventing catastrophic
stroke.
Keywords: DOCK8 deficiency, Hyperimmunity, Hyperimmunoglobulin E syndrome, Moyamoya, Mycophenolate
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Background
Primary immunodeficiency disorders are genetic diseases
that result in a defective immune system [1]. Affected in-
dividuals are predisposed to severe infections complicated
by the coexistence of hyperimmunity, which results in
various autoimmune and inflammatory disorders [2–4].
Hyperimmunoglobulin E syndrome (HIES) is a type of
primary immunodeficiency characterized by elevated
levels of IgE antibody, eczema, and recurrent staphylococ-
cal infections [5, 6]. Two disease entities have been identi-
fied: an autosomal dominant form caused by a STAT3
gene mutation (OMIM#102582) [7] and an autosomal
recessive form primarily caused by a loss-of-function mu-
tation in the dedicator of cytokinesis 8 (DOCK8) gene
(OMIM#611432) [8, 9]. The latter condition was identified
as a distinct disease entity even before its diagnosis could
be confirmed by genetic testing [10] and is characterized
by persistent viral skin infections and mucocutaneous can-
didiasis [8, 9]. A mutation in the tyrosine kinase 2 gene
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(OMIM#176941) has also been described, but only in one
patient who had an unusual susceptibility to viral and
mycobacterial infections [11].
HIES is associated with a wide spectrum of vascular ab-
normalities [12, 13]. The mechanism by which DOCK8
deficiency, in particular, affects patients appears to be
related to underlying autoimmunity caused by partial T
cell deficiency, resulting in dysregulation and leading to
elevated risks of developing both systemic and central ner-
vous system (CNS) vasculitis [14, 15]. The role of hyper-
eosinophilia in the development of vascular anomalies has
yet to be investigated [15]. Despite this association, cases
of vasculitis and CNS involvement associated with
DOCK8 mutations have been reported only sporadically
in the literature [8, 16], which is a major drawback with
respect to the development of effective therapies for these
vasculitides. No guidelines are available for the treatment
of patients with CNS vasculitis complicating a primary
immunodeficiency disorder. Currently, the most accepted
approach for treating such patients is to adapt an im-
munosuppressive protocol developed by Hutchinson et al.
[17] and designed to treat patients with primary CNS
vasculitis. However, said protocol may be inappropriate
for patients with an underlying immunodeficiency.
In this report, we describe the challenges of treating a
patient with CNS vasculitis in the context of immuno-
deficiency associated with a DOCK8 gene deletion.
Case presentation
A Yemeni female born to consanguineous parents pre-
sented at the age of 6 years with eczema, recurrent
bronchopneumonia, and skin abscesses. Additionally,
she exhibited persistent Molluscum contagiosum infec-
tions of the skin and recurrences of Herpes zoster in-
volving multiple dermatomes.
Immunological analysis revealed leukocytosis at
31 × 109/L (4.0–12.0), extreme peripheral eosinophilia
as high as 18,000 × 109/L (0–0.5), an elevated serum
IgE level of 41,000 IU/ml (0–52 IU/ml), and an ele-
vated IgG level of 2,530 mg/dl (400–1,600 mg/dl).
Magnetic resonance imaging (MRI) demonstrated the
presence of right frontal white matter and basal ganglia
hyperintensities consistent with previous infarcts (Fig. 1a).
Based on her clinical presentation, she was evaluated for
DOCK8 gene deletion. Sequencing of the DOCK8 gene by
polymerase chain reaction (PCR) and multiplex ligation
probe amplification (MLPA), performed as previously de-
scribed [9], revealed the presence of a large homozygous
deletion of the gene on chromosome 9, consistent with
the diagnosis of DOCK8 gene deletion. The patient’s par-
ents were heterozygous and a younger brother was homo-
zygous for this mutation. The patient’s initial treatment
consisted of prophylactic medications, including trimetho-
prim/sulfamethoxazole (co-trimoxazole), itraconazole, and
acyclovir. A monthly intravenous immunoglobulin infu-
sion was initiated at a dosage of 500 mg/kg body weight.
However, she had not been compliant with her monthly
infusions.
The patient was stable for two years prior to her
current presentation at the age of 8 years, when she
was found to have dysphasia and visual hallucinations
lasting for 3 weeks, as well as acute left eye squinting,
ipsilateral ptosis, and fatigue. Her last immunoglobulin
infusion was administered 2 months prior. During this
3-week period, the patient had sought advice from mul-
tiple services, including the neurology and ophthalmology
outpatient services. She was diagnosed with neuritis of the
third oculomotor nerve, which was thought to be caused
by the inflammatory nature of her underlying disease and
was managed conservatively. The patient continued to be
unwell and further developed dizziness, unsteady gait, and
excessive sleepiness, for which she was brought to the
emergency room and was admitted with a presumptive
diagnosis of encephalitis. Upon admission, the patient was
physically examined and was noted to have an ill appear-
ance, with an oral temperature of 38.4 °C. Her skin had no
Fig. 1 The brain MRI findings of a patient affected by CNS vasculitis and stroke. a A baseline MRI image showing T2 hyperintensities involving
the right frontal white matter and basal ganglia. b Analysis performed following the diagnosis of CNS vasculitis, demonstrating multiple high
signal intensity lesions in the periventricular deep and subcortical white matter. c The characteristic appearance of moyamoya phenomena-induced
vasculopathy is noted. d Nine days later, following the development of stroke symptoms, additional changes consistent with white matter
demyelination were identified. e Three months later, there were improvements in the high signal intensity lesions and no recurrences of infarction
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active herpetic or vasculitic lesions but showed signs of
severe dermatitis on the back and buttocks and ec-
zematous eruptions on the flexures of the arms and
popliteal region (Fig. 2a and b). Her neurological exam-
ination was significant for left oculomotor nerve and
left upper motor neuron facial palsy. Upper and lower
limb muscle power were each 4/5, with bilaterally exag-
gerated tone and reflexes.
Laboratory tests showed a white blood cell count of
16.6 × 109/L, a hemoglobin level of 10.4 g/dl, and a platelet
count of 875 × 109/L. The erythrocyte sedimentation rate
was 25 mm/h. Her cerebrospinal fluid was colorless, with
no cells, normal glucose and protein levels and a negative
gram stain. Extensive microbiological testing of the cere-
brospinal fluid and blood was performed and yielded
negative results (Table 1). An autoimmune diagnostic
work-up yielded a high antinuclear antibody titer (1:640)
with a speckled immunofluorescence pattern; however,
the results were negative for antineutrophil cytoplasmic
antibody, anticardiolipin antibody, antiphospholipid anti-
body, and lupus anticoagulant. The patient’s complement
levels, protein C and S levels, and coagulation profiles
were normal. Electroencephalography revealed no epilep-
tiform discharges. MRI demonstrated an increase in white
matter periventricular high signal intensity lesions com-
pared with previous images (Fig. 1b). Diffusion-weighted
imaging (DWI) revealed diffusion restriction characteristic
of acute ischemia (not shown). Magnetic resonance angi-
ography (MRA) indicated narrowing and occlusion of the
right middle cerebral and internal carotid arteries, with
multiple collateral vessels giving the appearance of a “puff
of smoke”, features consistent with moyamoya vasculopa-
thy (Fig. 1c). These findings were suggestive of a vascular
insult characteristic of vasculitis. No brain biopsy or con-
ventional cerebral angiography was performed because of
the lack of test facilities.
Fig. 2 Representative pictures of the dermatitis and eczematous lesions on the back, buttocks and flexures of the patient before therapy (a, b) and
12 months into steroid and MMF therapy (c, d)
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The patient was administered combined immunosup-
pressive therapy. The treatment consisted of an induc-
tion phase in which pulses of steroids were administered
at a dose of 30 mg/kg/day (maximum of 1 g/day) for
5 days, followed by a maintenance phase in which 2 mg/
kg/day (maximum of 60 mg/day) of oral steroids was
administered. Mycophenolate mofetil (MMF) was initi-
ated at a dose of 800 mg/m2/day in two divided doses
and continued throughout the maintenance phase. This
therapeutic approach was modified from that described
in the international childhood CNS vasculitis outcome
study [17]. Antimicrobial agents, including ceftriaxone,
vancomycin and acyclovir, were administered for the
first 72 h but were discontinued after ruling out infec-
tious agents.
The patient made remarkable progress and was able to
regain full consciousness and activity by the third day of
the steroid-pulse phase. A cranial nerve examination
demonstrated gradual improvement in her neurological
deficits. However, at 1 week following the initiation of
immunosuppressive therapy, the patient developed apha-
sia and left-sided hemiparesis that more greatly affected
the faciobrachial region and spared the lower extremity. A
repeat MRI demonstrated more extensive white matter
changes suggestive of an acute cortical infarct (Fig. 1d),
and DWI identified marginal restrictions in the parietal re-
gion and blooming artifacts in the parietal periventricular
region, findings suggestive of secondary hemorrhagic
changes (not shown).
Based on this deterioration, acetylsalicylic acid was
added to the patient’s regimen at an initial dose of
5 mg/kg, followed by a reduced dose of 3 mg/kg, which
profoundly improved her condition. During the next
several months, her neurological deficits improved, and
she regained most of her neurological function except
for some residual distal weakness. A follow-up MRI
performed 3 months following this vascular event revealed
improvements in the high-signal lesions and no new
lesions or either acute or sub-acute infarcts (Fig. 1e).
Steroid therapy was gradually tapered every 4 weeks (60-
50-40-30-25-20-17.5-15-12.5-10-7.5-5-2.5-0 mg/day) and
was successfully stopped over a 12 month period. The pa-
tient received vitamin D and calcium supplementation
while she was on steroids. She continued on the combined
MMF and acetylsalicylic acid therapy for 18 months, after
which she was completely weaned from MMF over an-
other 6-month period. Prophylactic aspirin at a dose of
1 mg/kg/day was continued for the prevention of possible
future cerebrovascular events. We monitored the pa-
tient for 2 years following the vasculitis and stroke
events. She remains symptom-free, and no vasculitis or
infectious flare-ups have occurred. In fact, she has
shown remarkable improvements in her eczema and
skin dermatitis lesions (Fig. 2c and d). The clinical pro-
gression of the patient while on the CNS vasculitis
protocol is illustrated in Fig. 3.
Discussion
Loss-of-function mutations in the DOCK8 gene cause a
rare form of primary immunodeficiency [8, 9]. Patients
carrying these mutations have a unique hyperimmune
system that predisposes them to a wide spectrum of
maladies [14, 15]. Various vascular anomalies have been
reported in both forms of HIES, including aneurysms,
vascular ectasia, and vascular thrombotic events [12].
However, CNS vasculitis [8] and moyamoya [16] are
most frequently encountered in patients with DOCK8
deficiency. Brain abnormalities have also been frequently
reported in these patients and manifest as MRI hyperin-
tensities [13]. These hyperintensities were observed in
our patient and were attributed to old infarcts.
The literature lacks sufficient reports on CNS vasculitis
associated with immunodeficiency disorders. Additionally,
there is no definitive treatment protocol for such patients.
Therefore, the development of new standardized thera-
peutic approaches for the management of this condition is
imperative. In this report, we described the case of a
young female affected by CNS vasculitis associated with
DOCK8 deficiency and described her responses to MMF
and corticosteroid therapy. This is the first report to de-
scribe the clinical presentation and outcome of a patient
Table 1 Laboratory investigation
Patient result Patient result
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Polyomavirus JC (JCV) Negative
West Nile virus Negative
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with primary immunodeficiency complicated by CNS vas-
culitis treated with specific immunosuppressive agents.
Managing patients with CNS vasculitis in the context
of a defective immune system is extremely challenging.
Clinicians are confronted by the need to aggressively
immunosuppress such patients. However, this approach
may result in further suppression of an already weak-
ened immune system. Therefore, careful consideration
is necessary when selecting an immune suppressant.
Immunosuppressive therapy protocols for childhood
primary vasculitis have been published previously [17].
The immunosuppressants employed included intravenous
cyclophosphamide and steroids during the induction
phase, followed by maintenance therapy with either MMF
or azathioprine and a subsequent steroid taper [17]. In
contrast, we started our patient on MMF for both the in-
duction and maintenance phases.
MMF is a prodrug that is well known for its immuno-
suppressive effects, which are mainly exerted through
the inhibition of inosine monophosphate dehydrogen-
ase, a rate-limiting enzyme involved in the de novo syn-
thesis of purine nucleotides [18]. As lymphocytes are
highly dependent on this enzyme for their proliferation,
MMF is considered a lymphocyte-selective agent that
causes inhibition of lymphocytes proliferation, immune
suppression, and inhibition of antibody production
[18]. The potent anti-inflammatory activity of this drug
is mediated through several mechanisms, including the
inhibition of proinflammatory cytokine production and
the expression of adhesion molecules, resulting in block-
ing of the recruitment of immune cells to the site of
inflammation [19]. Interestingly, this anti-inflammatory
property is believed to have a neuroprotective effect in
ischemic stroke, as has been demonstrated in experimen-
tal models [19, 20]. In one report, the use of MMF in
stroke-affected rat models resulted in decreases in the
signal intensities and volumes of infarcts observed on
DWI and an increase in the motor performance of the
animals [19].
MMF was selected for the treatment of our patient
for both induction and maintenance in an attempt to
reduce the risk of infection, given the compound's rela-
tively mild immunosuppressive activity compared with
cyclophosphamide and its better safety profile [21]. The
patient tolerated the compound well and exhibited no
significant adverse effects related to her therapy, with
the exception of hypokalemia, which was managed with
oral potassium supplementation. To date, our patient
has not experienced any significant illnesses, including
flare-ups of her skin infections, and presented a notice-
able improvement in her skin condition while receiving
this therapy. Most importantly, the treatment was ef-
fective in reversing most of the patient’s neurological
deficits.
One important consideration regarding the manage-
ment of patients with CNS vasculitis is the potential
development of stroke due to vessel inflammation and
stenosis [22, 23]. In our patient, stroke occurred later,
following an initial improvement. Early recognition of
the neurological signs of CNS vasculitis and the
prompt treatment of this condition, which should in-
clude aggressive management of the disease's initial
inflammation, would allow for increased control over
the disease's progression. We started our patient on
800 mg/m2/day of MMF; however, the immunosup-
pressive effect could have been optimized by increasing
StrokeImprovement CNSvasculitisClinical progress
Treatment
Pulse steroid Oral steroid
Aspirin










1 2 3 4 5 6 7 6 12 18 24
MMF
Day Month
Calcium and vitamin D
* Drowsy
* Oculomotor
   nerve palsy
* Bulbar palsy
* Unable to walk
* Active
* Improved cranial nerve deficit
* Able to walk
Fig. 3 Overview of the progress and therapeutic response of a patient with DOCK8 deletion and CNS vasculitis. Note: The solid line indicates full
doses of the medications whereas the dashed line indicates tapered doses
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the dosage of the drug as the therapeutic dose ranges
from from 800–1,200 mg/m2/day.
Furthermore, our patient was started on low-dose as-
pirin as an anticoagulation therapy for the management of
her stroke. Aspirin at a low dose has both antiplatelet and
anti-inflammatory properties that are mediated by an in-
creased level of plasma nitric oxide [24] and inhibition of
platelet COX-1-dependent thromboxane formation [25].
Inflammation and thrombosis play key roles in the de-
velopment of CNS vasculitis and stroke [23]. Aspirin
has been considered a standard therapy in children with
stroke [26], however, its use in the treatment of CNS
vasculitis or for the prevention of stroke in such pa-
tients has not been studied.
Additionally, moyamoya, a steno-occlusive cerebral
angiopathy resulting in vascular collateral formation
[27], was noted in our patient. DOCK8-deficient patients
reportedly develop moyamoya [16], which is considered
a consequence of ischemia. However, recent reports have
suggested the presence of an underlying autoimmune
disease process related to T cell dysregulation in these
patients, particularly in patients with unilateral disease,
as in our patient [28]. Knowledge of medical manage-
ment and revascularization procedures for patients
similar to ours is unfortunately lacking. Notably, cau-
tion should be exercised when prescribing antiplatelet
therapy to affected patients, as hemorrhage is a known
complication of moyamoya vasculopathies, especially
the hemorrhagic type [29]. Fortunately, the latter has
rarely been reported in children [29].
Our goal in reporting this case is to increase awareness
of primary immunodeficiency disorders and knowledge
regarding their natural histories and comorbidities. The
delay in recognizing the neurological comorbidity related
to DOCK8 deficiency in our patient likely contributed to
the occurrence of catastrophic stroke. We also emphasize
the importance of periodic screening for vascular events
even in asymptomatic patients, in addition to family
counseling about neurological symptoms. Moreover,
by reporting this case, we hope to outline a thera-
peutic approach to treating CNS vasculitis that may be
used successfully in immunosuppressed individuals.
The only definitive cure for immunodeficiency caused
by a DOCK8 gene deletion is hematopoietic stem cell
transplantation [30]; however, access to this treatment
may be an issue, either because of the unavailability of
a cross-matched donor or because of the lack of an
advanced immunology center to perform the proced-
ure. Therefore, it is important to develop alternative
and specific means of treating life-threatening events.
The potential development of cerebrovascular anomal-
ies and their complications in such patients must be
considered in the development of future therapeutic
approaches.
Conclusion
In conclusion, we have described both the clinical pres-
entation and the successful outcome of CNS vasculitis
treated with MMF and corticosteroids in a young child
with DOCK8 deficiency. Our report suggests that using
such an approach is both an effective and safe means of
treating autoimmunity and vasculitis. Recognition and
timely diagnosis, in addition to more aggressive manage-
ment of the disease’s initial inflammation, may prevent
complications.
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